Literature DB >> 20736924

B cells and transplantation tolerance.

Allan D Kirk1, Nicole A Turgeon, Neal N Iwakoshi.   

Abstract

Transplantation tolerance is a state of immune unresponsiveness (or benign responsiveness) to the presence of specific, nonself antigens in the absence of chronic immunosuppressive therapy. Renal transplant tolerance remains a desired yet generally unattained goal that would enable transplantation to be performed without the risk of graft rejection or the need for broadly immunosuppressive drugs, which can have toxic effects. Studies published in the past few years have provided evidence that B cells have an important role in both graft rejection and transplantation tolerance. Indeed, antibody-dependent and antibody-independent functions of B cells account for both tolerogenic and rejection-promoting immune responses in transplant recipients. This Review comprises a discussion of the mechanisms involved in the induction of B-cell tolerance and a survey of current and emerging therapies that target the effects of B cells in transplant recipients.

Mesh:

Substances:

Year:  2010        PMID: 20736924     DOI: 10.1038/nrneph.2010.111

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  124 in total

1.  Actively acquired tolerance of foreign cells.

Authors:  R E BILLINGHAM; L BRENT; P B MEDAWAR
Journal:  Nature       Date:  1953-10-03       Impact factor: 49.962

2.  Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

Authors:  Herwig-Ulf Meier-Kriesche; Jesse D Schold; Titte R Srinivas; Bruce Kaplan
Journal:  Am J Transplant       Date:  2004-03       Impact factor: 8.086

3.  Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways.

Authors:  Kenneth Cardona; Gregory S Korbutt; Zvonimir Milas; James Lyon; Jose Cano; Wanhong Jiang; Hameeda Bello-Laborn; Brad Hacquoil; Elizabeth Strobert; Shivaprakash Gangappa; Collin J Weber; Thomas C Pearson; Ray V Rajotte; Christian P Larsen
Journal:  Nat Med       Date:  2006-02-26       Impact factor: 53.440

4.  A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

Authors:  F Vincenti; B Charpentier; Y Vanrenterghem; L Rostaing; B Bresnahan; P Darji; P Massari; G A Mondragon-Ramirez; M Agarwal; G Di Russo; C-S Lin; P Garg; C P Larsen
Journal:  Am J Transplant       Date:  2010-03       Impact factor: 8.086

5.  Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics.

Authors:  Carlos A Vieira; Avinash Agarwal; Benita K Book; Richard A Sidner; Christopher M Bearden; Howard M Gebel; Anthony L Roggero; Naomi S Fineberg; Timothy Taber; Michael A Kraus; Mark D Pescovitz
Journal:  Transplantation       Date:  2004-02-27       Impact factor: 4.939

Review 6.  Humoral theory of transplantation.

Authors:  Paul I Terasaki
Journal:  Am J Transplant       Date:  2003-06       Impact factor: 8.086

7.  Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.

Authors:  Lorraine C Racusen; Robert B Colvin; Kim Solez; Michael J Mihatsch; Philip F Halloran; Patricia M Campbell; Michael J Cecka; Jean-Pierre Cosyns; Anthony J Demetris; Michael C Fishbein; Agnes Fogo; Peter Furness; Ian W Gibson; Denis Glotz; Pekka Hayry; Lawrence Hunsickern; Michael Kashgarian; Ronald Kerman; Alex J Magil; Robert Montgomery; Kunio Morozumi; Volker Nickeleit; Parmjeet Randhawa; Heinz Regele; Daniel Seron; Surya Seshan; Stale Sund; Kiril Trpkov
Journal:  Am J Transplant       Date:  2003-06       Impact factor: 8.086

Review 8.  Costimulatory pathways in transplantation: challenges and new developments.

Authors:  Xian C Li; David M Rothstein; Mohamed H Sayegh
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

9.  Cell to cell interaction in the immune response. I. Hemolysin-forming cells in neonatally thymectomized mice reconstituted with thymus or thoracic duct lymphocytes.

Authors:  J F Miller; G F Mitchell
Journal:  J Exp Med       Date:  1968-10-01       Impact factor: 14.307

10.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

View more
  20 in total

1.  Interleukin-10 From Marginal Zone Precursor B-Cell Subset Is Required for Costimulatory Blockade-Induced Transplantation Tolerance.

Authors:  Girdhari Lal; Yumi Nakayama; Apoorva Sethi; Amit K Singh; Bryna E Burrell; Neeraja Kulkarni; C Colin Brinkman; Daiki Iwami; Tianshu Zhang; Jonathan S Bromberg
Journal:  Transplantation       Date:  2015-09       Impact factor: 4.939

Review 2.  Biologic agents in islet transplantation.

Authors:  Boris Gala-Lopez; Andrew R Pepper; A M James Shapiro
Journal:  Curr Diab Rep       Date:  2013-10       Impact factor: 4.810

Review 3.  Targeting B cells and antibody in transplantation.

Authors:  M R Clatworthy
Journal:  Am J Transplant       Date:  2011-06-10       Impact factor: 8.086

4.  Elevated serum levels of B-cell activating factor in pediatric renal transplant patients.

Authors:  Anja Lehnhardt; Franziska Dunst; Michael van Husen; Sebastian Loos; Jun Oh; Thomas Eiermann; Martina Koch; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2012-03-28       Impact factor: 3.714

5.  Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection.

Authors:  Gemma Banham; Davide Prezzi; Sarah Harford; Craig J Taylor; Rizwan Hamer; Rob Higgins; J Andrew Bradley; Menna R Clatworthy
Journal:  Transplantation       Date:  2013-08-27       Impact factor: 4.939

6.  Inotuzumab ozogamicin murine analog-mediated B-cell depletion reduces anti-islet allo- and autoimmune responses.

Authors:  Michele Carvello; Alessandra Petrelli; Andrea Vergani; Kang Mi Lee; Sara Tezza; Melissa Chin; Elena Orsenigo; Carlo Staudacher; Antonio Secchi; Kyri Dunussi-Joannopoulos; Mohamed H Sayegh; James F Markmann; Paolo Fiorina
Journal:  Diabetes       Date:  2011-11-10       Impact factor: 9.461

7.  B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells.

Authors:  S Heidt; J Hester; S Shankar; P J Friend; K J Wood
Journal:  Am J Transplant       Date:  2012-03-15       Impact factor: 8.086

Review 8.  Myeloid and Mesenchymal Stem Cell Therapies for Solid Organ Transplant Tolerance.

Authors:  Jennifer Li; Angus W Thomson; Natasha M Rogers
Journal:  Transplantation       Date:  2021-12-01       Impact factor: 5.385

9.  A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft.

Authors:  Daniel Baron; Gérard Ramstein; Mélanie Chesneau; Yann Echasseriau; Annaick Pallier; Chloé Paul; Nicolas Degauque; Maria P Hernandez-Fuentes; Alberto Sanchez-Fueyo; Kenneth A Newell; Magali Giral; Jean-Paul Soulillou; Rémi Houlgatte; Sophie Brouard
Journal:  Kidney Int       Date:  2015-01-28       Impact factor: 10.612

Review 10.  Nuclear antigens and auto/alloantibody responses: friend or foe in transplant immunology.

Authors:  Toshiaki Nakano; Chao-Long Chen; Shigeru Goto
Journal:  Clin Dev Immunol       Date:  2013-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.